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Hospital-based use of 
thromboprophylaxis in 
patients with COVID-19
Physicians are receiving a great deal 
of information regarding how to care 
for patients with coronavirus disease 
2019 (COVID-19). We would like 
to offer further information about 
thromboprophylaxis that we believe 
is worth considering when treating 
patients who have been admitted to 
hospital with COVID-19.
Tang and colleagues1 described a 
consecutive series of 183 patients 
who had been admitted to hospital 
with COVID-19 in China. Activation 
of the coagulation system was found 
in many patients, and the degree of 
activation (defined as, for example, 
increased D-dimer concentrations at 
time of admission) was significantly 
higher in patients who did not 
survive than those who did survive. 
Overall, 21 (11%) of 183 patients died. 
15 (71%) of 21 non-survivors and 
only one (1%) of 162 survivors met 
criteria for disseminated intravascular 
coagulation during their hospital stay. 
In a case series from China,2 increased 
D-dimer concentration at time of 
admission to hospital (>1 µg/mL) was 
associated with a risk of in-hospital 
mortality that was 18 times higher than 
among those with normal D-dimer 
concentrations, and the authors high-
lighted that “inadequate adherence to 
standard supportive therapy”, among 
other things, might have led to poor 
outcomes in some patients.2
Acutely ill patients with severe viral 
pneumonia and acute respiratory 
distress syndrome (ARDS), such as 
those with H1N1 infection, who have 
been admitted to hospital have a 
23-times increased risk for pulmonary 
embolism,3 and guidelines support 
routine thromboprophylaxis in 
these patients.4 Increased D-dimer 
concentrations of more than double 
the upper limit of normal has emerged 
as a new biomarker to predict risk 
of venous thromboembolism in all 
patients in hospitals. Trial subgroup 
analyses, in which increased D-dimer 
concentration or admission to hospital 
with infection (particularly pneumonia) 
were incorporated as variables, show 
that extended thromboprophylaxis 
with direct oral anticoagulants has 
benefit compared with routine in-
hospital thromboprophylaxis with low 
molecular weight heparin.5 Finally, 
empirical anticoagulation has been 
associated with improved thrombotic 
event-free survival in critically ill 
patients with ARDS due to influenza A 
H1N1.3
In light of this evidence, and the 
fact that hospitals might soon have 
a large number of patients with 
COVID-19 who might meet guideline 
requirements for thromboprophylaxis, 
we believe it seems prudent to use 
thromboprophylaxis in such patients, 
particularly those with evidence of 
activation of the coagulation system 
(eg, increased D-dimer concentrations) 
on admission.
Of utmost importance will be 
the prospective, real-time data 
collection to assess whether use of 
thromboprophylaxis in patients with 
COVID-19 leads to improved outcomes, 
including improved survival, without 
clinically important bleeding.
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